- Home
- NXC vs NTRB Comparison
NXC vs NTRB Comparison
Compare NXC & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NXC | NTRB |
|---|---|---|
| Founded | 1992 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.2M | 71.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NXC | NTRB |
|---|---|---|
| Price | $13.15 | $5.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 17.5K | ★ 23.0K |
| Earning Date | 01-01-0001 | 12-11-2025 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | N/A | ★ $2,278,321.00 |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | $70.47 | ★ N/A |
| Revenue Growth | N/A | ★ 12.69 |
| 52 Week Low | $11.86 | $3.72 |
| 52 Week High | $13.70 | $11.78 |
Technical Indicators
Market Signals| Indicator | NXC | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 39.61 | 41.94 |
| Support Level | $13.13 | $4.60 |
| Resistance Level | $13.23 | $5.45 |
| Average True Range (ATR) | 0.08 | 0.35 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 7.14 | 49.23 |
Price Performance
Historical ComparisonAbout NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing in municipal obligations.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.